Download Free Levels And Trends Of Contraceptive Use As Assessed In 1998 Book in PDF and EPUB Free Download. You can read online Levels And Trends Of Contraceptive Use As Assessed In 1998 and write the review.

This report covers 142 countries, representing 92 per cent of the world population. It examines the prevalence of contraceptive use at national, regional and global levels. Trends in contraceptive use from the 1970s are analysed for 86 countries. Specific methods of contraception are also examined: female sterilization accounts for a third, IUD for 22 per cent, and the oral pill 14 per cent. The report also includes estimates of the growth in contraceptive practice required if fertility is to decline in line with the UN population projections in "World population prospects: the 1998 revision" (1999, ISBN 9211513332)
This is the fifth report in the series of publications which examine the prevalence of contraceptive use around the world. It contains data covering 160 countries, including 125 developing countries and 35 developed countries, representing 96 per cent of the world population. The review is based primarily on data obtained from nationally representative sample surveys, and includes two new chapters analysing contraceptive use dynamics and national policies relating to fertility, contraception and population growth.
The main contents are key findings and messages regarding the relationship between contraceptive use and fertility, for 195 countries or areas of the world. These highlights will draw mainly from World Population Prospects 2019, and model-based estimates and projections of family planning indicators 2019. Policy-related implications of and responses to trends in family planning and fertility will be integrated throughout the text. In particular, these issues are of relevance for contextualizing Sustainable Development Goals 3.7.1. and 3.7.2. and the achievement of the 2030 Agenda.
More than a quarter of pregnancies worldwide are unintended. Between 1995 and 2000, nearly 700,000 women died and many more experienced illness, injury, and disability as a result of unintended pregnancy. Children born from unplanned conception are at greater risk of low birth weight, of being abused, and of not receiving sufficient resources for healthy development. A wider range of contraceptive options is needed to address the changing needs of the populations of the world across the reproductive life cycle, but this unmet need has not been a major priority of the research community and pharmaceutical industry. New Frontiers in Contraceptive Research: A Blueprint for Action, a new report from the Institute of Medicine of the National Academies, identifies priority areas for research to develop new contraceptives. The report highlights new technologies and approaches to biomedical research, including genomics and proteomics, which hold particular promise for developing new products. It also identifies impediments to drug development that must be addressed. Research sponsors, both public and private, will find topics of interest among the recommendations, which are diverse but interconnected and important for improving the range of contraceptive products, their efficacy, and their acceptability.
According to the classic and widely accepted statement by Hauser and Duncan (1959: 2), demography is defined as “the study of the size, territorial distribution, and components of population, changes therein, and components of such changes.” Almost all disciplines of social sciences and most disciplines of natural sciences deal with human beings in one way or another, either directly or indirectly. Furthermore, demographic concepts (e.g., birth rate, death rate, and migration) and methods and analysis strategies (e.g., life table analysis) can be readily extended to other species (insects, animals, plants, etc.) and inanimate collectives (enterprises, automobiles, etc.). Clearly, demography is an important thematic field in science and it may provide the empirical foundation for studying human beings, animals, and inanimate collectives on which other relevant scientific research is built. The volume aims to be of value to the various audiences of both non-specialists and experts who seek a comprehensive understanding of issues related to human population. As reviewed in the very beginning of the Theme Introduction, “interdisciplinary” is one of the three major features of demography. Given the rapid development in techniques for collecting not only demographic data but also other related data concerning health, biomarkers, genetics, behaviors, and social and natural environments in conventional population surveys, as well as rapidly enhancing computing powers, this volume shows and concludes that demography will be even more interdisciplinary in the coming decades. A notable example is that the cross-field “marriage” between bio-medical sciences and demography will lead us to enter an era in which bio-medical and demographic methods will be well integrated. As indicated by James R. Carey and James W. Vaupel in Chapter 13 of this volume, the bio-demographic branches of demography are vibrant areas of demographic research that are rapidly growing and that have great potential to enrich and enlarge the domain of demography. Not only can demographers learn much from biologists and epidemiologists, but demographers can contribute much to research on life in general and to research on population health. The increasing availability of data sources and much enhanced computing/internet power will also lead demography to be more interactive with the other fields, such as psychology, environmental science, economics, business and management, etc. As discussed in this volume’s Chapter 11 by Swanson and Pol, for example, it is now possible to link conventional demographic data sources of census, surveys, and vital statistics with administrative records such as social security, tax reporting, medical insurance, hospital records, school registration, supermarket purchasing cards use, etc., while protecting individuals’ privacy. Such linkages will substantially increase the value of demographic methods, surveys and administrative records for scientific research and policy analysis, as well as the applicability of demography in business and governmental decision making processes.
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Experts estimate that nearly 60 percent of all U.S. pregnancies--and 81 percent of pregnancies among adolescents--are unintended. Yet the topic of preventing these unintended pregnancies has long been treated gingerly because of personal sensitivities and public controversies, especially the angry debate over abortion. Additionally, child welfare advocates long have overlooked the connection between pregnancy planning and the improved well-being of families and communities that results when children are wanted. Now, current issues--health care and welfare reform, and the new international focus on population--are drawing attention to the consequences of unintended pregnancy. In this climate The Best Intentions offers a timely exploration of family planning issues from a distinguished panel of experts. This committee sheds much-needed light on the questions and controversies surrounding unintended pregnancy. The book offers specific recommendations to put the United States on par with other developed nations in terms of contraceptive attitudes and policies, and it considers the effectiveness of over 20 pregnancy prevention programs. The Best Intentions explores problematic definitions--"unintended" versus "unwanted" versus "mistimed"--and presents data on pregnancy rates and trends. The book also summarizes the health and social consequences of unintended pregnancies, for both men and women, and for the children they bear. Why does unintended pregnancy occur? In discussions of "reasons behind the rates," the book examines Americans' ambivalence about sexuality and the many other social, cultural, religious, and economic factors that affect our approach to contraception. The committee explores the complicated web of peer pressure, life aspirations, and notions of romance that shape an individual's decisions about sex, contraception, and pregnancy. And the book looks at such practical issues as the attitudes of doctors toward birth control and the place of contraception in both health insurance and "managed care." The Best Intentions offers frank discussion, synthesis of data, and policy recommendations on one of today's most sensitive social topics. This book will be important to policymakers, health and social service personnel, foundation executives, opinion leaders, researchers, and concerned individuals. May
Provides a comprehensive assessment of the scientific evidence on prevalence and the resulting health effects of a range of exposures that are know to be hazardous to human health, including childhood and maternal undernutrition, nutritional and physiological risk factors for adult health, addictive substances, sexual and reproductive health risks, and risks in the physical environments of households and communities, as well as among workers. This book is the culmination of over four years of scientific equiry and data collection, know as the comparative risk assessment (CRA) project.
Andrology for the Clinician consists of two parts: In Part One, the busy clinician can easily find the problem-orientated information he or she needs on such issues as male factor fertility problems, male contraception, and male genital tract infection and tumours. Part Two contains in-depth subject-orientated information and adds important scientific background information to the recommendations received in Part One. Several leading experts have contributed to this work, which has been extensively subedited by world-renowned editors to ensure a well-structured didactic design and homogeneous content. This outstanding book is of great value for all Urologists, Andrologists, Dermatologists, Endocrinologists, Gynaecologists, Reproductive Biologists, GPs, Gerontologists, Psychologists, Psychiatrists, Paediatricians and anyone else interested in the problems of male sex and constitution.